Hyperthermic peritoneal perfusion

Koga, S., Hamazoe, R., Maeta, M., Shimizu, N, Murakami, A., and Wakatsuki,T. (1988), Prophylactic therapy for peritoneal recurrence of gastric cancer by continuous hyperthermic peritoneal perfusion with mitomycin C, Cancer, 61,232. 

Pharmacokinetic Principles 33 Dose-Response Relationship 34 Intraperitoneal Application 34 Intra-arterial Application 34 Isolated Perfusion Techniques Application Techniques 35 Intracavitary Application 35 Intra-arterial Infusion 36 Regional Perfusion Techniques Stop-Flow Perfusions 36 Isolated Extremity Perfusion (ILP) 37 Hyperthermic Peritoneal Perfusion (HIPEC) 38 Clinical Indications 38 Pancreas Carcinoma 38 Bronchial Carcinoma 39 Extremity Sarcoma 40 Peritoneum 41 Surgical Technique 41 Rationale 42 Clinical Results 43 References 44 Further Reading 45... 

For second-line treatment no definite therapy has yet been defined. The combination of secondary cytoreduction plus hyperthermic peritoneal perfusion constitutes a feasible and effective option for this subset of patients. Several phase II trials have been published showing a positive effect of second cytoreductive surgery on survival of patients with recurrent or persistent epithelial ovarian cancer. At this moment the role intraoperative hyperthermic peritoneal perfusion is not clear and has to be determined in a prospective randomized trial. 

---